Skip to main content

KALA

Stock
Health Care
Biotechnology

Performance overview

KALA Price
Price Chart

Forward-looking statistics

Beta
0.95
Risk
90.38%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Company info

SectorHealth Care
IndustryBiotechnology
Employees77
Market cap$18.5M

Fundamentals

Enterprise value$20.8M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity566.73

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.36
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$359K
Avg trading volume (10 day)$607K
Put-call ratio

Macro factor sensitivity

Growth-1.2
Credit+9.0
Liquidity+1.7
Inflation-5.5
Commodities-2.4
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio-0.76
Price to sales
P/E Ratio-0.76
Enterprise Value to Revenue
Price to book5.76

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research (December 16, 2024)
Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals Inc KALA shares are trading higher Thursday. The stock appears to be moving on continued momentum after the company on Wednesday announced FDA acceptance of an investigational new drug (IND) application for KPI-012 for the treatment of persistent corneal epithelial defect.

Benzinga (December 29, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free